StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
301501.SZ$30.36-4.47%
Fair $30.36+0.0%

301501.SZ

Hefei Hengxin Life Science and Technology Co., Ltd.

Consumer Cyclical / Packaging & ContainersShenzhen

$30.36

-1.42 (-4.47%)

Fairly Valued+0.0%Fair Value $30.36Fund rank 27/100 · Data gapFallback financials|
SA 42/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-110.9M · quality 56.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 22/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

42/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 301501.SZLocal privado en este navegador · Hefei Hengxin Life Science and Technology Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4.5B

P/E

24.5x

↑

EV/EBITDA

10.1x

↑

ROE

10.6%

↑

Gross Margin

24.0%

↓

Debt/Equity

0.10

↓
52-Week Range$30
$28$71

TradingView lightweight chart

301501.SZ price, volumen y niveles de valoración

Último $31.78Periodo -35.5%
Fair value: $30.36

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+19.2%

FCF CAGR

—

FCF margin

-10.2%

FCF / Net income

-0.84x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.84B · net income $223.8M · FCF $-188.4M

2022-FY → 2025-FY

Gross margin

24.0%-4.1% pts

Operating margin

13.8%-4.2% pts

Net margin

12.1%-2.8% pts

FCF margin

-10.2%-10.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.84B$1.84B$1.59B$1.43B$1.09B
Net Income$223.8M$223.8M$219.9M$213.9M$162.8M
EBITDA$406.2M$406.2M$356.9M$318.9M$239.1M
EPS1.611.611.981.931.47
Gross Margin24.0%24.0%26.3%28.6%28.1%
Operating Margin13.8%13.8%16.7%18.9%18.0%
Net Margin12.1%12.1%13.8%15.0%15.0%
Balance Sheet
Debt/Equity0.100.100.390.320.29
Current Ratio2.312.31———
Cash Flow
Free Cash Flow$-188.4M$-188.4M$-78.7M$-110.9M$2.6M
Returns
ROE10.6%10.6%21.0%26.0%26.7%
Valuation
P/E24.4824.48———
EV/EBITDA10.1010.10———
P/B2.002.00———
Growth & Yield
Revenue Growth15.7%15.7%11.9%30.9%—
EPS Growth-18.6%-18.6%2.8%31.2%—
Dividend Yield1.1%1.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

18.6%

exigente

EPS terminal req.

$2.69

Spread vs growth

-37.2%

5Y implied EPS CAGR

15.1%

exigente

EPS terminal req.

$3.26

Spread vs growth

-33.6%

10Y implied EPS CAGR

12.5%

razonable

EPS terminal req.

$5.25

Spread vs growth

-31.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -46.9%

Total return

-46.9%

Start / end P/E

29.4x → 18.8x

EPS bridge

1.98 → 1.61

Residual

+6.7%

EPS growth-18.6%
Multiple rerating-36.1%
Dividend+1.1%
Residual / FX / buybacks / cross-term+6.7%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.